Diagnostic Center | May 20, 2024
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi approved by USFDA
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Subscribe To Our Newsletter & Stay Updated